MediPharm Labs Enters Denmark Health-related Cannabis Marketplace, Secures New White-Label Provide Prospects

bunch of red fruits

TORONTO, Sept. 01, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a worldwide leader in specialized, investigation-driven pharmaceutical-high-quality cannabis extraction, distillation and derivative solutions, nowadays announced it will provide cannabis concentrate solutions in Denmark to two new healthcare cannabis shoppers beneath two separate white-label agreements. These shoppers will be serviced by each GMP authorized facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ very first provide agreements for the export of completed solutions to Denmark.

Denmark granted individuals legal access to cannabis-primarily based medicinal solutions two years ago as element of a 4-year pilot system. The system offers individuals with secure item access and national overall health authorities with patient information that they can use to fully grasp usage and efficacy. According to details complied by New Frontier Information and the Danish Ministry of Well being, more than two,one hundred individuals (mainly girls involving the ages of 42-64) received cannabis-primarily based medicinal solutions from 429 prescribing physicians beneath this system in 2019.

“The express goal of establishing a multi-jurisdictional, GMP-certified production capability is to lead the worldwide cannabis market place for medicinal, wellness and adult use applications and these agreements represent a further step forward in realizing our ambitions,” mentioned Pat McCutcheon, CEO, MediPharm Labs. “Getting in on the ground floor of the Danish healthcare market place with new and revolutionary healthcare cannabis focused solutions positions us for further development in Europe and adds to MediPharm Labs all-vital physique of expertise that we are leveraging to improve the style of our formulations for individuals and shoppers everywhere.”

Below the agreements, one particular which has an initial two-year term and the second a one particular-year term – each topic to renewal, MediPharm Labs will provide a complete variety of specially formulated CBD and THC cannabis oil solutions that will be white-labeled for distribution.

MediPharm Labs anticipates delivery to its shoppers to start in October 2020, pending regulatory approval by applicable overall health authorities.

GMP Certification Ignites Development for MediPharm Labs Australia

“Since the starting of 2020, MediPharm Labs Australia has secured a number of extremely appealing domestic and international provide agreements with higher high-quality partners, now which includes new shoppers in Denmark,” mentioned Warren Everitt, CEO, MediPharm Labs Australia. “This volume and the pace of new organization wins are a clear and vital validation of our selection to develop a GMP certified cannabis extraction facility provide chain for planet markets and a testament to MediPharm Labs expanding profile and reputation. We appear forward to ramping up production beneath all of these agreements.”

MediPharm Labs Australia received its Great Manufacturing Practice (“GMP”) certificate from the Therapeutic Goods Association in Might 2020, which enables it to sell cannabis APIs and completed solutions to nations across the EU, which includes Denmark. The Organization entered into its very first European white-label cannabis provide agreement that similar month with Therismos Restricted.

About Denmark’s Health-related Cannabis Marketplace

Denmark launched its 4-year healthcare cannabis pilot system on January 1st, 20181. Post-harvest Great Manufacturing Processes (GMP) is expected for distribution of healthcare cannabis solutions in Denmarktwo.

By way of the system, physicians can prescribe healthcare cannabis for all purposes and are guided by suggestions in 4 regions: discomfort triggered by a number of sclerosis, discomfort triggered by spinal cord harm, side effects from chemotherapy therapy and neuropathic discomfort that is due to brain, spinal cord or nerve harmthree. The recommendations published by the Danish Medicines Agency are primarily based on an in depth evaluation of literature as properly as assessments of: cannabis schemes in the Netherlands, Canada and Israel prior cannabis drug approvals in Europe and the US and scientific proof by the National Academy of Sciences (USA, 2017).

About MediPharm Labs Corp.

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical high-quality cannabis oil and concentrates and sophisticated derivative solutions using a Great Manufacturing Practices certified facility with ISO typical constructed clean rooms. MediPharm Labs has invested in an specialist, investigation-driven group, state-of-the-art technologies, downstream purification methodologies and goal-constructed facilities with 5 principal extraction lines for delivery of pure, trusted and precision -dosed cannabis solutions for its shoppers. By way of its wholesale and white label platforms, they formulate, customer-test, procedure, package and distribute cannabis extracts and sophisticated cannabinoid-primarily based solutions to domestic and international markets. As a worldwide leader, MediPharm Labs has completed industrial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.

For additional details, please speak to:
Laura Lepore, VP, Investor Relations
Phone: 705-719-7425 ext 1525
E-mail: [email protected]
Web site: www.medipharmlabs.com

______________________________
1 Medicinal Cannabis Pilot System. Retrieved: https://laegemiddelstyrelsen.dk/en/specific/medicinal-cannabis/citizens/medicinal-cannabis-pilot-programme/
two The Health-related Cannabis Marketplace in Denmark &amp Europe. Retrieved: https://www.openaccessgovernment.org/the-healthcare-cannabis-market place-in-denmark-europe/80721/
three The Danish Health-related Cannabis Pilot Programme: Placing the Patient Initially. Retrieved: https://www.healtheuropa.eu/the-danish-healthcare-cannabis-pilot-programme-placing-the-patient-very first/92991/

CAUTIONARY NOTE With regards to FORWARD-Searching Info:

This news release consists of “forward-hunting information” and “forward-hunting statements” (collectively, “forward-hunting statements”) inside the which means of the applicable Canadian securities legislation. All statements, other than statements of historical reality, are forward-hunting statements and are primarily based on expectations, estimates and projections as at the date of this news release. Any statement that entails discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or overall performance (typically but not generally employing phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that specific actions, events or benefits “may” or “could”, “would”, “might” or “will” be taken to take place or be accomplished) are not statements of historical reality and may possibly be forward-hunting statements. In this news release, forward-hunting statements relate to, amongst other items, the effective overall performance of the agreements and shipping of solutions thereunder as planned further development in Europe and enhancing the style of formulations. Forward-hunting statements are necessarily primarily based upon a quantity of estimates and assumptions that, although viewed as affordable, are topic to recognized and unknown dangers, uncertainties, and other variables which may possibly bring about the actual benefits and future events to differ materially from these expressed or implied by such forward-hunting statements. Such variables consist of, but are not restricted to: common organization, financial, competitive, political and social uncertainties the inability of MediPharm Labs to acquire sufficient financing the delay or failure to get regulatory approvals and other variables discussed in MediPharm Labs’ filings, accessible on the SEDAR web site at www.sedar.com. There can be no assurance that such statements will prove to be precise, as actual benefits and future events could differ materially from these anticipated in such statements. Accordingly, readers ought to not location undue reliance on the forward-hunting statements and details contained in this news release. Except as expected by law, MediPharm Labs assumes no obligation to update the forward-hunting statements of beliefs, opinions, projections, or other variables, ought to they alter.

Primary Logo

If You Liked This Write-up Click To Share

.mobile_tx{show: none}
#ax1x{
font-size: 1.1em
font-weight: bold
line-height: 1.five
clear:each
margin: 0px 0px 20px 1% !vital
min-height: four.5em
text-transform: uppercase
padding: .25em 10px
position: relative
width: 98%
float: left
}
.subsequent-pg {
height: 85px !vital
width: one hundred%
border-leading-left-radius: 3px
border-bottom-left-radius: 3px
background-colour: #e5192c
background-image: url(‘/wp-content material/themes/mh-magazine/photos/worldwide-following.png’) !vital
background-repeat: no-repeat
background-position: proper center
background-size: auto one hundred%
overflow: hidden
box-sizing: border-box
margin-bottom: 0px
margin-leading: 10px
position: relative
padding-left: 100px
}
.subsequent-pg::just before {
width: 45px !vital
height: 85px !vital
show: block
content material: “”
width: 32px
height: 64px
background-image: url(‘/wp-content material/themes/mh-magazine/photos/worldwide-just before.png’) !vital
background-repeat: no-repeat
background-position: proper center
background-size: auto one hundred%
position: absolute
left: -4px
leading: 0px
}
.action-txt {
text-transform: uppercase
margin: 12px
line-height: 61px
text-align: left
font-size: 36px
background-repeat: no-repeat
background-position: proper center
background-size: 26px 18px
colour: #FFF
float: left
font-weight: bold
font-loved ones: “Open Sans”,sans-serif !vital
width: 78%
show: inline-block
text-align: center
}
@media (max-width: 768px){
.mobile_tx{show: block}
.desktop_tx{show: none}
.pps-slider-nav .pps-subsequent {
text-align: center
position: static
padding: 5px 20px
float: left
width: one hundred%
box-sizing: border-box
}
.pps-subsequent .subsequent-short article-web page {
padding-left:
float: left
margin:
}
.subsequent-short article-web page .action-txt {
padding-left: !vital
text-align: center
width: 87%
box-sizing: border-box
font-size: 26px
background:
text-align: center
}
#ax1x {
padding: .25em !vital
min-height: two.3em
width: one hundred% !vital
margin: 0px !vital
margin-bottom: 15px !vital
padding-bottom: !vital
}
}
@media (max-width: 500px){
.subsequent-short article-web page .action-txt{
width: 75%
}
}

Latest posts